期刊文献+

雷帕霉素抑制人肝癌细胞HepG-2侵袭能力的实验研究 被引量:1

Studies of antitumor effect of rapamycin on human hepatocellular carcinoma HepG-2 cells in vitro.
下载PDF
导出
摘要 目的观察雷帕霉素(Rapamycin)体外对肝癌HepG-2细胞侵袭能力的影响。方法用不同浓度的雷帕霉素作用于体外培养的HepG-2细胞,应用Matrigel胶模拟基质检测细胞侵袭能力。结果雷帕霉素能显著降低肿瘤细胞的侵袭能力,随剂量增高降低越明显。各药物处理组与阴性对照组相比差异具有统计学意义(P<0.05)。结论雷帕霉素能有效地降低肝癌细胞HepG-2的侵袭能力。 Objective To investigate the effect of cell invasion ability induced by rapamycin on human hepatocellular carcinoma HepG-2 cells.Methods HepG-2 cells in vitro were given different concentrations of rapamycin,and the invasion ability of HepG-2 cells was observed by Matrigel.Results Rapamycin could inhibit the invasion ability of HepG-2 cells,and and the inhibit presented dose-dependent relationship.There was significantly different between rapamycin given groups and control group.Conclusion Rapamycin significantly inhibits the invasion ability of HepG-2 cells.
出处 《海南医学》 CAS 2011年第11期122-123,共2页 Hainan Medical Journal
关键词 雷帕霉素 增殖 侵袭 Rapamycin Proliferation Invasion
  • 相关文献

参考文献7

  • 1Raught B,Gingras AC,Sonenberg N.The target of rapamycin (TOR) proteins[J].PNAS,2001,98(13):7037-7044.
  • 2Shamji AF,Nghiem P,Schreiber SL.Integration of growth factor and nutrient signaling:implications for cancer biology[J].Mol Cell,2003,12(2):271-280.
  • 3Rathmell WK,Wright TM,Rini BL.Molecularly targeted therapy in renal cell carcinoma[J].Expert Rev Anticancer Ther,2005,5(6):1031-1040.
  • 4Stephan S,Datta K,Wang E,et al.Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer[J].Clin Cancer Res,2004,10(20):6993-7000.
  • 5Giannelli G,Bergamirfi C,Fransvea E,et al.Human hepatocelular carcinoma (HCC) cells require both alpha-betal integrin and matrix metalloproteinases activity for migration and invasion[J].Lab Invest,2001,81(4):613-627.
  • 6仵正,吕毅,刘原兴,王作仁.雷帕霉素对小鼠H_(22)肝癌细胞生长增殖的影响[J].西安交通大学学报(医学版),2009,30(6):672-676. 被引量:3
  • 7王征,樊嘉,周俭,吴志全,邱双健,余耀,黄晓武,汤钊猷.雷帕霉素抑制肝癌细胞生长及转移的实验研究[J].中华医学杂志,2006,86(24):1666-1670. 被引量:8

二级参考文献22

  • 1周俭,樊嘉,吴志全,邱双健,王征,黄晓武,余耀,贺轶锋,汤钊猷,王玉琦.单中心连续203例肝移植临床疗效分析[J].中华医学杂志,2005,85(26):1805-1808. 被引量:13
  • 2CALNE RY. Liver transplantation for liver cancer [J]. World J Surg, 1982, 6(1):76-80.
  • 3RINGE B, WITTEKIND C, BECHSTEIN WO, et al. The role of liver transplantation in hepatobiliary malignancy [J]. Ann Surg, 1989, 209..88.
  • 4MAZZAFERRO V, REGALIA E, DOCI R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis [J]. N Engl J Med, 1996, 334(11): 693-699.
  • 5BERETTA L, GINGRAS AC, SVITKIN YV, et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation [J]. EMBO J, 1996, 15 (3): 658-664.
  • 6SABATINI DM, PIERCHALA BA, BARROW RK, et al. The rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity [J]. J Biol Chem, 1995, 270 (36) 20875-20878.
  • 7SCHUMACHER G, OIDTMANN M, ROSEWICZ S, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth [J]. Transplant Proc, 2002, 34(5) : 1392-1393.
  • 8GUBA M, VON BREITENBUCH P, STEINBAUER M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor [J]. Nat Med, 2002, 8(2):128-35.
  • 9WANG Z, ZHOU J, FAN J, et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma [J]. J Cancer Res Clin Oncol, 2009,135(5):715-722.
  • 10ZHOU J, WANG Z, WU ZQ, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatoeellular carcinoma exceeding the Milan criteria [J]. Transpl Proc, 2008, 40(10) :3548-3553.

共引文献9

同被引文献24

  • 1Levine B,Kroemer G. Autophagy in the pathogenesis of disease[J].{H}CELL,2008,(01):27-42.
  • 2Komatsu M,Waguri S,Ueno T. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice[J].{H}Journal of Cell Biology,2005,(03):425-434.
  • 3Hippert MM,O'Toole PS,Thorburn A. Autophagy in cancer:Good,bad,or both[J].{H}Cancer Research,2006,(19):9349-9351.
  • 4Ogier-Denis E,Codogno P. Autophagy:A barrier or an adaptive response to cancer[J].{H}Biochimica et Biophysica Acta,2003,(02):113-128.
  • 5Sharma N,Thomas S,Golden EB. Inhibition of autophagy and induction of breast cancer cell death by mefloquine,an antimalarial agent[J].{H}Cancer letters,2012,(02):143-154.
  • 6Driscoll J J,Chowdhury RD. Molecular crosstalk between the proteasome,aggresomes and autophagy:Translational potential and clinical implications[J].{H}Cancer letters,2012,(02):147-154.
  • 7Yang S,Wang X,Contino G. Pancreatic cancers require autophagy for tumor growth[J].{H}Genes and development,2011,(07):717-729.
  • 8Furuya N,Yu J,Byfield M. The evolutionarily eonserved domain of Beclin 1 is required for Vps34 binding,autophagy and tumor suppressor function[J].{H}AUTOPHAGY,2005,(01):46-52.
  • 9Degenhardt K,Mathew R,Beaudoin B. Autophagy promotes tumor cell survival and restricts necrosis,inflammation,and tumorigenesis[J].{H}CANCER CELLS,2006,(01):51-64.
  • 10Parikh S,Hyman D. Hepatocellular cancer:A guide for the internist[J].{H}American Journal of Medicine,2007,(03):194-202.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部